Preview

Онкогематология

Расширенный поиск

Дазатиниб: 10 лет применения в мировой клинической практике

https://doi.org/10.17650/1818-8346-2016-11-1-24-33

Полный текст:

Аннотация

В статье представлены результаты метаанализа данных литературы в отношении опыта использования ингибитора тирозинкиназ 2-го поколения дазатиниба, а также итоги клинических исследований применения дазатиниба у больных хроническим миелолейкозом при резистентности и непереносимости иматиниба в различных фазах заболевания. Приведены результаты, в том числе отдаленные, сравнительного анализа использования дазатиниба и иматиниба в 1-й линии терапии у больных с впервые выявленным хроническим миелолейкозом. Проанализированы спектр и частота побочных явлений, представлены рекомендации по управлению токсичностью дазатиниба. Описаны перспективы возможной отмены терапии дазатинибом у больных хроническим миелолейкозом с глубоким молекулярным ответом – ведения фазы ремиссии без лечения. Также представлена информация о результатах использования дазатиниба при лечении острых лимфобластных лейкозов с филадельфийской хромосомой.

Об авторах

К. М. Абдулкадыров
ФГБУ «Российский научно-исследовательский институт гематологии и трансфузиологии ФМБА России»; Россия, 191024, Санкт-Петербург, ул. 2-я Советская, 16
Россия


В. А. Шуваев
ФГБУ «Российский научно-исследовательский институт гематологии и трансфузиологии ФМБА России»; Россия, 191024, Санкт-Петербург, ул. 2-я Советская, 16
Россия


И. С. Мартынкевич
ФГБУ «Российский научно-исследовательский институт гематологии и трансфузиологии ФМБА России»; Россия, 191024, Санкт-Петербург, ул. 2-я Советская, 16
Россия


Список литературы

1. Tokarski J. S., Newitt J. A., Chang C. Y. et al. The structure of dasatinib (BMS- 354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 2006;66(11):5790–7.

2. Lombardo L. J., Lee F. Y., Chen P. et al. Discovery of N-(2-chloro-6-methylphenyl)- 2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin- 4-ylamino)thiazole-5-carboxamide (BMS- 354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004;47(27):6658–61.

3. Спрайсел® (Sprycel®). Инструкция по применению, противопоказания, состав и цена. Справочник лекарств РЛС (Электронный ресурс). URL: www.rlsnet.ru/tn_index_id_38851.htm#pokazaniya-preparata-sprajsel® (дата обращения 01.01.2016). [Spraysel® (Sprycel®). Instructions for use, contraindications, composition and price. Medication guide RLS (Electronic source). URL: http://www.rlsnet.ru/tn_index_ id_38851. htm#pokazaniya-preparatasprajsel ® (Access date 01.01.2016). (In Russ.)].

4. Verstovsek S., Tefferi A., Cortes J. et al. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 2008;14(12):3906–15.

5. Hahn N. M., Knudsen B. S., Daneshmand S. et al. Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity. Urol Oncol 2016;34(1):4. e11–7.

6. Druker B. J., Guilhot F., O’Brien S. G. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New Engl J Med 2006;355(23):2408–17.

7. Абдулкадыров К. М., Абдуллаев А. О., Авдеева Л. Б. и др. Федеральные клинические рекомендации по диагностике и терапии хронического миелолейкоза. Вестник гематологии 2013;9(3):4–40.

8. [Abdulkadyrov K. M., Abdullaev A. O., Avdeeva L. B. et al. Fedеral clinical guidelines for chronic myelogenous leukemia diagnosis and treatment. Vestnik gematologii = Bulletin of Hematology 2013;9(3):4–40. (In Russ.)].

9. Saglio G., Kim D. W., Issaragrisil S. et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. New Engl J Med 2010;362(24):2251–9.

10. Jabbour E., Kantarjian H. M., Saglio G. et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 2013;123(4): 494–500.

11. Lahaye T., Riehm B., Berger U. et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center. Cancer 2005;103(8):1659–69.

12. Bristol-Myers Squibb Announces Extension of U. S. Agreement for ABILIFY® and Establishment of an Oncology Collaboration with Otsuka. Bristol-Myers Squibb 2009 06.04.2009 (Electronic source). URL: http://news.bms.com/press-release/financial-news/bristol-myers-squibbannounces-extension-us-agreement-abilifyand-estab (Access date 01.01.2016).

13. Das J., Chen P., Norris D. et al. 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)] -2-methyl-4-pyrimidinyl] amino)]- 1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J Med Chem 2006;49(23):6819–32.

14. Shah N. P., Tran C., Lee F. Y. et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305(5682):399–401.

15. O'Hare T., Walters D. K., Stoffregen E. P. et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65(11):4500–5.

16. Redaelli S., Piazza R., Rostagno R. et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 2009;27(3):469–71.

17. Sprycel (dasatinib) tablets prescribing information and patient information. Bristol Mayers-Squibb Company. Princeton, NJ, 2011.

18. Trivedi D., Landsman-Blumberg P., Darkow T. et al. Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment. J Manag Care Spec Pharm 2014;20(10):1006–15.

19. FDA approves additional medical indication for Sprycel. Patients with rare type of leukemia now have another treatment option FDA news release 2010 (Electronic source). URL: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm231409.htm (Access date 01.01.2016).

20. Talpaz M., Shah N. P., Kantarjian H. et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. New Engl J Med 2006;354(24):2531–41.

21. Baccarani M., Mauro M. J., Cervantes F. et al. Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C). J Clin Oncol 2008;26(15S): 1.

22. Kantarjian H., Pasquini R., Lévy V. et al. Dasatinib or high-dose imatinib for chronicphase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily. Cancer 2009;115(18):4136–47.

23. Guilhot F., Apperley J., Kim D. W. et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 2007;109(10):4143–50.

24. Cortes J., Rousselot P., Kim D. W. et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007;109(8):3207–13.

25. Shah N. P., Kantarjian H. M., Kim D. W. et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008;26(19):3204–12.

26. Porkka K., Khoury H. J., Paquette R. L. et al. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer 2010;116(2):377–86.

27. Kantarjan H., Shah N. P., Kim D. W. et al. Six-year (yr) follow-up of patients (pts) with imatinib-resistant or -intolerant chro icphase chronic myeloid leukemia (CML-CP) receiving dasatinib. J Clin Oncol 2012;30(suppl):abstr 6506.

28. Kantarjian H., Cortes J., Kim D. W. et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 2009;113(25):6322–9.

29. Lilly M. B., Ottmann O. G., Shah N. P. et al. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. Am J Hematol 2010;85(3):164–70.

30. Pemmaraju N., O'Brien S., Borthakur G. et al. Results of a phase II trial of dasatinib as frontline therapy for chronic myeloid leukemia (CML) in chronic phase (CP). Blood 2014;121(21):abstr 4565.

31. Cortes J. E., Jones D., O'Brien S. et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 2010;28(3):398–404.

32. Kantarjian H., Shah N. P., Hochhaus A. et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. New Engl J Med 2010;362(24):2260–70.

33. Cortes J., Saglio G., Baccarani M. et al. Final Study results of the phase 3 dasatinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) trial (DASISION, CA180-056). Blood 2014;124(21):152.

34. Kantarjian H. M., Shah N. P., Cortes J. E. et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012;119(5):1123–9.

35. Radich J. P., Kopecky K. J., Appelbaum F. R. et al. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood 2012;120(19):3898–905.

36. Shah N. P., Guilhot F., Cortes J. E. et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood 2014;123(15):2317–24.

37. Quintás-Cardama A., Han X., Kantarjian H. et al. Tyrosine kinase inhibitorinduced platelet dysfunction in patients with chronic myeloid leukemia. Blood 2009;114(2):261–3.

38. Gratacap M. P., Martin V., Valéra M. C. et al. The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. Blood 2009;114(9):1884–92.

39. Quintás-Cardama A., Kantarjian H., Ravandi F. et al. Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer 2009;115(11):2482–90.

40. Jabbour E., Makenbaeva D., Lingohr- Smith M. et al. Evaluation of comorbidities relevant to tyrosine kinase inhibitor treatment among patients with chronic myelogenous leukemia in the U. S. managed care setting. Blood 2014;124(21):4550.

41. Brixey A. G., Light R. W. Pleural effusions due to dasatinib. Curr Opin Pulm Med 2010;16(4):351–6.

42. Iriyama N., Fujisawa S., Hagihara M. et al. The incidence of pleural effusion on dasatinib treatment is associated with CD56 positive cell values one month after commencing dasatinib and achievement of an early molecular response in newly diagnosed chronic myeloid leukemia patients. Blood 2014;124(21):3142.

43. Quintás-Cardama A., Kantarjian H., O’Brien S. et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007;25(25):3908–14.

44. Valent P., Hadzijusufovic E., Schernthaner G. H. et al. Vascular safety issues in CML patients treated with BCR/ ABL1 kinase inhibitors. Blood 2014;125(6):901–6.

45. Chai-Adisaksopha C., Lam W., Hillis C. Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis. Leuk Lymphoma 2015:1–11. [Epub ahead of print].

46. Nicolini F. E., Turkina A., Shen Z. X. et al. Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase. Cancer 2012;118(1):118–26.

47. Larson R. A., Kim D. W., Issaragrisil S. et al. Efficacy and safety of nilotinib (NIL) vs imatinib (IM) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): long-term follow-up (f/u) of ENESTnd. Blood 2014;124(21):4541.

48. Hochhaus A., Kantarjian H. The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients. J Cancer Res Clin Oncol 2013;139(12):1971–84.

49. Cortes J. E., Kim D. W., Pinilla-Ibarz J. et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. New Engl J Med 2013;369(19):1783–96.

50. McLaughlin V. V., Archer S. L., Badesch D. B. et al. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. J Am Coll Cardiol 2009;53(17):1573–619.

51. Montani D., Bergot E., Günther S. et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012;125(17):2128–37.

52. Sano M., Saotome M., Urushida T. et al. Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia – critical alert. Intern Med 2012;51(17):2337–40.

53. Rasheed W., Flaim B., Seymour J. F. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res 2009;33(6):861–4.

54. Zdenek R., Belohlavkova P., Cetkovsky P. Comparison of glucose and lipid metabolism abnormality during nilotinib, imatinib and dasatinib therapy – results of Enigma 2 study. Blood 2014;124(21):1813.

55. Agostino N. M., Chinchilli V. M., Lynch C. J. et al. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. J Oncol Pharm Pract 2011;17(3):197–202.

56. Breccia M., Muscaritoli M., Cannella L. et al. Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib. Leuk Res 2008;32(10):1626–8.

57. Mahon F. X., Rea D., Guilhot J. et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11(11):1029–35.

58. Ross D. M., Branford S., Seymour J. F. et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013;122(4):515–22.

59. Rea D., Nicolini F. E., Tulliez M. et al. Dasatinib or nilotinib discontinuation in chronic phase (CP) chronic myeloid leukemia (CML) patients (pts) with durably undetectable BCR-ABL transcripts: interim analysis of the STOP 2G-TKI study with a minimum follow-up of 12 months – on behalf of the French CML Group Filmc. Blood 2014;124(21):811.

60. Imagawa J., Tanaka H., Okada M. et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol 2015;2(12):e528–35.

61. Шуваев В. А., Абдулкадыров К. М., Мартынкевич И. С. и др. Фармакоэкономическое моделирование таргетной терапии у больных хроническим миелолейкозом в ремиссии. Онкогематология 2014;(3):16–24. [Shuvaev V. A., Abdulkadyrov K. M., Martynkevich I. S. et al. Pharmacoeconomic modeling of target therapy of chronic myeloid leukemia in remission. Onkogematologiya = Oncohematology 2014;(3):6–14. (In Russ.)].

62. Шуваев В. А., Абдулкадыров К. М., Мартынкевич И. С. и др. Выбор терапии первой линии хронического миелолейкоза: моделирование клинико-экономических факторов. Клиническая онкогематология 2015;8(1):78–83. [Shuvaev V. A., Abdulkadyrov K. M., Martynkevich I. S. et al. Choice of first line treatment of chronic myelogenous leukemia: modeling of clinical and economic factors. Klinicheskaya onkogematologiya = Clinical Oncohematology 2015;8(1):78–83 (In Russ.)].


Для цитирования:


Абдулкадыров К.М., Шуваев В.А., Мартынкевич И.С. Дазатиниб: 10 лет применения в мировой клинической практике. Онкогематология. 2016;11(1):24-33. https://doi.org/10.17650/1818-8346-2016-11-1-24-33

For citation:


Abdulkadyrov K.M., Shuvaev V.A., Martynkevich I.S. Dasatinib: ten years of clinical practice worldwide. Oncohematology. 2016;11(1):24-33. (In Russ.) https://doi.org/10.17650/1818-8346-2016-11-1-24-33

Просмотров: 380


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1818-8346 (Print)
ISSN 2413-4023 (Online)